|
|
Post by mango on Jan 21, 2023 12:00:55 GMT -5
Hey guys, let’s be real—a lot of folks have Castagna Derangement Syndrome and try to discredit MC for any success MannKind has.
Michael Castagna is responsible for getting Tyvaso DPI developed. Before Michael it was just a concept. Michael took that concept and got the drug developed and put it into Phase 1 clinical trial. Michael took an enormous risk pivoting away from Afrezza to Tyvaso DPI and orphan lung and the risk paid off handsomely. Thanks to Michael, United inked a deal with us because of the great success Phase 1 showed. Michael got us completely away from bankruptcy and we are now literally very close to profitability. We now have 4 growing revenue sources, a robust pipeline, a wonderful partner, plenty of capital and a growing PPS.
More someone who had hardly anything to work with coming in as CEO, he completely transformed the company into with it is today. Those technical pivots were key to success.
Hats off to Michael for making those key bets, taking plenty of low risk high reward bets too along the way that ultimately failed, but that’s how you learn. When you have passion, patience and persistence failures will eventually lead to success. Michael may have had some minor failures along the way like the Damon Dash, One Drop, Immex, NRx deals, but those were low risk high reward scenarios. Tyvaso DPI was a huge risk huge reward scenario and that one has paid off.
Congratulations Michael. Here’s hoping for some more big payoffs in the near and long term. Afrezza Pediatrics and Afrezza India will be complete soon and 4 INDs submitted within next 24 months. Good times ahead!
|
|
|
|
Post by runner on Jan 21, 2023 14:01:34 GMT -5
I am hoping that there will be an in-person shareholder meeting this spring so we can see and hear him and the other staff in person. The last in-person meeting was in New York in 2019.
|
|
|
|
Post by uvula on Jan 21, 2023 14:36:21 GMT -5
Great idea for a thread. We should also start a "Martine saved mnkd" thread. Then all of the pro mc and anti mc people will have a place to go to radicalize themselves and the rest of us can easily avoid these 2 threads.
|
|
|
|
Post by mango on Jan 21, 2023 14:49:49 GMT -5
Great idea for a thread. We should also start a "Martine saved mnkd" thread. Then all of the pro mc and anti mc people will have a place to go to radicalize themselves and the rest of us can easily avoid these 2 threads. Yet, here you are. |
|
|
|
Post by phdedieu12 on Jan 21, 2023 15:00:46 GMT -5
Great idea for a thread. We should also start a "Martine saved mnkd" thread. Then all of the pro mc and anti mc people will have a place to go to radicalize themselves and the rest of us can easily avoid these 2 threads. Easy, don't read or post on this thread... |
|
|
|
Post by sportsrancho on Jan 21, 2023 16:15:26 GMT -5
Great idea for a thread. We should also start a "Martine saved mnkd" thread. Then all of the pro mc and anti mc people will have a place to go to radicalize themselves and the rest of us can easily avoid these 2 threads. I don’t know about you, but I’m tired of the whole thing and I’m tired of the whole short thing. I’m tired of it all. I just wanna concentrate on business. And hope the stock goes up. It doesn’t matter who did what at this point, what matters is everybody is cooperating and trying to make things better for patients. Which will help us the shareholders. |
|
|
|
Post by radgray68 on Jan 21, 2023 17:36:26 GMT -5
I'm pretty sure, from listening to the last JPM event for the 10th time, the learning curve for our beginner CEO is over and we now have an experienced professional CEO who has his fingers on all the pulses at Mannkind. This guy has obviously put in his 10,000 hours. All I'm gonna say
😁
|
|
|
|
Post by caesar on Jan 21, 2023 18:15:06 GMT -5
Regarding Mike Castagna; he's the MAN - cut him a break! It's obvious that when it comes to making money of this stock, everybody has an opinion, but very few on this board has ever attempted to right a sinking ship. So going forward, everyone should try to be "Stoic" and wait for the ship to land at each one of our docks. For all the past machinations:
“Think of yourself as dead. You have lived your life. Now take what’s left and live it properly.” — Marcus Aurelius, Meditations
|
|
|
|
Post by sayhey24 on Jan 21, 2023 19:27:50 GMT -5
Lets see how Mike does this year. He started at MNKD on 3/14/2016. The closing pps was $6.95. The closing pps on 1/20/2023 was $4.75.
Last week he outlined his 2023 plans for afrezza. The plan for T1s was to submit the kids study results in 2024. There was no T2 afrezza plan. The 2023 T2 plan was to put V-Go in the sales reps "bag" last week.
In another thread I outlined 2 things which are focused and achievable in 2023 and can be presented at ADA2023; Afrezza as a rescue tool; and a "treat to target" T2 protocol. Both could change the SoC and together would make in-roads into the T1 and T2 market without disrupting BP too much. Can Mike get this done?
Mango - as far as Tyvaso DPI we have to give credit where credit is do. Martine already made the market with Tyvaso and was looking at several options for a DPI. Thanks to Sol Steiner's work technosphere won out and now looks to be headed to becoming a major success. Sales and market penetration are now up to Martine.
What are the 4 growing revenue sources? I only counted 3 from Mike's slide; Tyvaso DPI; afrezza; V-GO. What is the fourth?
|
|
|
|
Post by hellodolly on Jan 21, 2023 20:50:08 GMT -5
I'm pretty sure, from listening to the last JPM event for the 10th time, the learning curve for our beginner CEO is over and we now have an experienced professional CEO who has his fingers on all the pulses at Mannkind. This guy has obviously put in his 10,000 hours. All I'm gonna say 😁 Malcolm Gladwell reference? Anyways, if not OK. Either way, check out a great book that will have you glued to it from front to back written by Gladwell called, "Outliers". My favorite chapter in the book is all about NHL players, as kids and what made the difference from those picked to play on the best teams from the rest of the pack at very young ages (9-10 years old) and how that contributed to the unique disparity in months of birth, in hockey. Let's just say a new term was coined after this book and it's called, "Red-shirting your kindergartner." I agree with you on the review of the JPM presentation. I've listened to that call several times, reviewed the slide deck as well and haven't been more excited about the future of MNKD. He's not only got his fingers on the pulse but, he's building his legacy around real and tangible goals that are just now beginning to come into more focus thanks to the JPM presentation. Additionally, we easily have several "needle moving catalysts" coming this year, primarily those around each EC as growth in revenue looks to increase based on the current trends in both Afrezza and Tyvaso, along with advancements in additional clinical assets and a possible announcement of a second UTHR drug candidate. I look forward to what Mike thinks he can do with the results of the India trials besides an Afrezza launch in India? More empirical evidence for CDER and the FDA for their label change consideration? A lot of money spent and resources committed to that trial, started around the same time the FDA and MNKD began to collaborate on the label change as part of the FDAs Model-Informed Drug Development (MIDD) pilot program? Maybe just my wild speculation. |
|
|
|
Post by Clement on Jan 22, 2023 7:37:08 GMT -5
Lets see how Mike does this year. He started at MNKD on 3/14/2016. The closing pps was $6.95. The closing pps on 1/20/2023 was $4.75. Last week he outlined his 2023 plans for afrezza. The plan for T1s was to submit the kids study results in 2024. There was no T2 afrezza plan. The 2023 T2 plan was to put V-Go in the sales reps "bag" last week. In another thread I outlined 2 things which are focused and achievable in 2023 and can be presented at ADA2023; Afrezza as a rescue tool; and a "treat to target" T2 protocol. Both could change the SoC and together would make in-roads into the T1 and T2 market without disrupting BP too much. Can Mike get this done? Mango - as far as Tyvaso DPI we have to give credit where credit is do. Martine already made the market with Tyvaso and was looking at several options for a DPI. Thanks to Sol Steiner's work technosphere won out and now looks to be headed to becoming a major success. Sales and market penetration are now up to Martine. What are the 4 growing revenue sources? I only counted 3 from Mike's slide; Tyvaso DPI; afrezza; V-GO. What is the fourth? slide 5 of Q3 2022 EC investors.mannkindcorp.com/static-files/92d4a5eb-72b6-4527-9951-6e613d4edac8 |
|
|
|
Post by phdedieu12 on Jan 22, 2023 10:14:16 GMT -5
Lets see how Mike does this year. He started at MNKD on 3/14/2016. The closing pps was $6.95. The closing pps on 1/20/2023 was $4.75. Last week he outlined his 2023 plans for afrezza. The plan for T1s was to submit the kids study results in 2024. There was no T2 afrezza plan. The 2023 T2 plan was to put V-Go in the sales reps "bag" last week. In another thread I outlined 2 things which are focused and achievable in 2023 and can be presented at ADA2023; Afrezza as a rescue tool; and a "treat to target" T2 protocol. Both could change the SoC and together would make in-roads into the T1 and T2 market without disrupting BP too much. Can Mike get this done? Mango - as far as Tyvaso DPI we have to give credit where credit is do. Martine already made the market with Tyvaso and was looking at several options for a DPI. Thanks to Sol Steiner's work technosphere won out and now looks to be headed to becoming a major success. Sales and market penetration are now up to Martine. What are the 4 growing revenue sources? I only counted 3 from Mike's slide; Tyvaso DPI; afrezza; V-GO. What is the fourth? slide 5 of Q3 2022 EC investors.mannkindcorp.com/static-files/92d4a5eb-72b6-4527-9951-6e613d4edac81,2,3 and 4, yes all there! Spot on Clement |
|
|
|
Post by phdedieu12 on Jan 22, 2023 10:35:56 GMT -5
Regarding Mike Castagna; he's the MAN - cut him a break! It's obvious that when it comes to making money of this stock, everybody has an opinion, but very few on this board has ever attempted to right a sinking ship. So going forward, everyone should try to be "Stoic" and wait for the ship to land at each one of our docks. For all the past machinations: “Think of yourself as dead. You have lived your life. Now take what’s left and live it properly.” — Marcus Aurelius, Meditations What I find interesting and that gets lost is his dedication to the cause. You have a CEO that believes in this company and product so much that when everyone was running for the exits, he showed up, he actually wanted to job, refused to go the bankruptcy route, saving all our investments in the process, and found a way to making this company and its products relevant. 6 years ago, NO ONE wanted any part of this sinking ship and Mike believed he could turn it around, and that he did! The point is Mike saved the company, no one else did! The decision to pivot and use TS for other molecules is Mike's doing, the calls to potential companies including UT is his doing, these are HIS decisions. That is the guy I want fighting for me, not some Johnny come lately. And this year is going to be opening some eyes!! |
|
|
|
Post by phdedieu12 on Jan 22, 2023 10:51:12 GMT -5
Hey guys, let’s be real—a lot of folks have Castagna Derangement Syndrome and try to discredit MC for any success MannKind has. Michael Castagna is responsible for getting Tyvaso DPI developed. Before Michael it was just a concept. Michael took that concept and got the drug developed and put it into Phase 1 clinical trial. Michael took an enormous risk pivoting away from Afrezza to Tyvaso DPI and orphan lung and the risk paid off handsomely. Thanks to Michael, United inked a deal with us because of the great success Phase 1 showed. Michael got us completely away from bankruptcy and we are now literally very close to profitability. We now have 4 growing revenue sources, a robust pipeline, a wonderful partner, plenty of capital and a growing PPS. More someone who had hardly anything to work with coming in as CEO, he completely transformed the company into with it is today. Those technical pivots were key to success. Hats off to Michael for making those key bets, taking plenty of low risk high reward bets too along the way that ultimately failed, but that’s how you learn. When you have passion, patience and persistence failures will eventually lead to success. Michael may have had some minor failures along the way like the Damon Dash, One Drop, Immex, NRx deals, but those were low risk high reward scenarios. Tyvaso DPI was a huge risk huge reward scenario and that one has paid off. Congratulations Michael. Here’s hoping for some more big payoffs in the near and long term. Afrezza Pediatrics and Afrezza India will be complete soon and 4 INDs submitted within next 24 months. Good times ahead! You are spot on Mango, DPI is ALL on Mike. He picked a winner, so now we're winning! |
|
|
|
Post by prcgorman2 on Jan 22, 2023 12:04:16 GMT -5
If we don’t have any more pandemics or other large scale challenges to business as usual, 2023 through 2025 can be the years where Mannkind finally rewards investors with substantial share price growth. I agree there need to be at least 4 material sources of revenue. Slide 5 from the 3Q earnings report claims 4, but I would argue it’s 3; Tyvaso DPI, Afrezza, and V-Go. I don’t think of royalties from Tyvaso DPI as a separate source from manufacturing and “collaboration”. If Tyvaso DPI were to go away, all of that goes away. It’s a 3rd source, not two sources. A fourth would be the RLS candidate if it got real. Another possible candidate is an inhalable version of the leprosy drug clofazimine. And last and probably not least is the unidentified molecule of interest to UTHR. Those are known candidates. There are possibly unknown candidates for a fourth source of revenue.
I may have “what have you done for me lately” syndrome, but I don’t think this is a time to rest on laurels. Mike has proven he has an undeniable work ethic. You don’t annex a doctorate in pharma and become CEO of a billion dollar company by being lucky. Mike has provided good leadership when that was paramount to survival. I’m sure he had help. Stephen Binder and Kent Kresa (and David Kendall) are no slouches. I don’t know if being a persistent hard working CEO means a fourth revenue source is forthcoming in 2023, but this investor would really like to see that happen. I’m just a Monday morning armchair CEO, but my gut says the 4th pillar is needed for the foundation.
|
|
